Home › Companies › CRISPR THERAPEUTICS AG › 2023-2024

CRISPR THERAPEUTICS AG 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and CRISPR THERAPEUTICS AG’s Form 8-K (Item 5.07 on EDGAR). Page generated 02 October 2026.

60Reported items
445Asset managers
5,335Fund votes
2024-05-30Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore CRISPR THERAPEUTICS AG in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by CRISPR THERAPEUTICS AG

These tallies are CRISPR THERAPEUTICS AG’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CRISPR THERAPEUTICS AG — official shareholder meeting results, meeting held 2024-05-30
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Samarth Kulkarni, Ph.D.	42,442,977	503,265	76,063	--	18,272,374	Majority: yes
Elect Director: Ali Behbahani, M.D.	28,820,247	14,118,172	83,886	--	18,272,374	Majority: yes
Elect Director: Maria Fardis, Ph.D.	42,253,383	689,281	79,641	--	18,272,374	Majority: yes
Elect Director: H Edward Fleming Jr., M.D.	35,393,629	7,547,609	81,067	--	18,272,374	Majority: yes
Elect Director: Simeon J. George, M.D.	33,809,769	9,131,338	81,198	--	18,272,374	Majority: yes
Elect Director: John T. Greene	34,903,054	8,038,359	80,892	--	18,272,374	Majority: yes
Elect Director: Katherine A. High, M.D.	42,672,595	274,928	74,782	--	18,272,374	Majority: yes
Elect Director: Douglas A. Treco, Ph.D.	40,807,871	2,133,551	80,883	--	18,272,374	Majority: yes
Elect Director: Sandesh Mahatme, LL.M.	42,762,070	177,633	82,602	--	18,272,374	Majority: yes
Elect Director: Christian Rommel, Ph.D.	42,777,061	162,398	82,846	--	18,272,374	Majority: yes
Elect Director: Ali Behbahani, M.D.	28,182,970	14,734,499	104,836	--	18,272,374	Majority: yes
Elect Director: H Edward Fleming Jr., M.D.	34,866,314	8,048,771	107,220	--	18,272,374	Majority: yes
Elect Director: Simeon J. George, M.D.	32,981,270	9,932,010	109,025	--	18,272,374	Majority: yes
Elect Director: John T. Greene	34,374,439	8,540,932	106,934	--	18,272,374	Majority: yes

This meeting is also recorded here as 2024-05-31; both records come from the same filing, so the date should be checked against it.

Source: CRISPR THERAPEUTICS AG, Form 8-K — read the filing on EDGAR.

How asset managers voted at the CRISPR THERAPEUTICS AG 2023-2024 meeting

Each item below shows how the 445 asset managers that disclosed a CRISPR THERAPEUTICS AG vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CRISPR THERAPEUTICS AG’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securities law requirements

SECTION 14A SAY-ON-PAY VOTESSECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-05-30.

Combines 16 wordings of this item as funds reported it.

77% fund support · no official result

FOR 77%AGAINST 23%

The 406 asset managers below cast 77% of the shares they voted on this item FOR (29,623,713 for, 8,805,788 against).

FOR: 29,623,713 (77.1%)AGAINST: 8,805,788 (22.9%)ABSTAIN: 3,357 (0.0%)UNKNOWN: 1,000 (0.0%)NOT VOTED: 102 (0.0%)

Largest asset managers voting on “Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securi” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
Capital Group	13,449,569	0	For
ARK ETF Trust	7,426,282	0	For
T. Rowe Price	3,612,195	132,793	For
Nikko Asset Management Americas, Inc.	0	2,970,301	Against
Charles Schwab	0	1,339,160	Against
SR ONE CAPITAL MANAGEMENT, LP	1,048,951	0	For
Vanguard	884,371	0	For
UBS	0	659,393	Against
Contrarius Investment Management Ltd	655,913	0	For
BlackRock	5,608	497,294	Against
Versant Venture Management, LLC	500,028	0	For
Avoro Capital Advisors LLC	419,580	0	For
Fidelity	0	376,541	Against
Man Group plc	0	323,770	Against
Nikko Asset Management Co., Ltd.	0	286,772	Against
State Street	280,809	2,441	For
CAPITAL ADVISORS INC/OK	231,592	0	For
BAILLIE GIFFORD & CO LTD	0	223,818	Against
Vestmark Advisory Solutions, Inc.	0	202,549	Against
Northern Trust	125,338	11,555	For
Allspring	0	130,762	Against
Equitable	124,294	1,170	For
Lazard	0	110,978	Against
BLAIR WILLIAM & CO/IL	0	99,996	Against
Natixis	89,596	399	For

Showing the 25 largest of 406 asset managers. See all 406 in the interactive database.

2. Non-binding advisory vote on the 2023 Compensation Report.

COMPENSATION

Meeting held 2024-05-30.

Combines 7 wordings of this item as funds reported it.

88% fund support · no official result

FOR 88%12%

The 76 asset managers below cast 88% of the shares they voted on this item FOR (10,479,272 for, 1,414,874 against).

FOR: 10,479,272 (88.1%)AGAINST: 1,414,874 (11.9%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Non-binding advisory vote on the 2023 Compensation Report.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
Capital Group	6,194,677	0	For
T. Rowe Price	1,445,748	42,642	For
SR ONE CAPITAL MANAGEMENT, LP	1,048,951	0	For
Vanguard	874,759	0	For
Charles Schwab	0	669,580	Against
Versant Venture Management, LLC	500,028	0	For
BlackRock	0	234,394	Against
Fidelity	0	142,631	Against
Equitable	124,294	1,170	For
State Street	107,434	0	For
Global X	0	75,358	Against
Lincoln Financial	74,808	0	For
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	29,503	0	For
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
Capitol Series Trust	0	18,000	Against
American Century	0	15,793	Against
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
AMERICAN BEACON FUNDS	11,871	0	For
Listed Funds Trust	0	10,557	Against
Goldman Sachs	10,005	0	For

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

3. Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2023 Compensation Report: Non-binding advisory vote on the 2023 Compensation Report

COMPENSATION

Meeting held 2024-05-30.

Combines 2 wordings of this item as funds reported it.

99.4% fund support · no official result

FOR 99.2%

The 69 asset managers below cast 99.4% of the shares they voted on this item FOR (7,984,030 for, 47,382 against).

FOR: 7,984,030 (99.3%)AGAINST: 47,382 (0.6%)ABSTAIN: 9,350 (0.1%)

Largest asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Abstain	Vote
ARK ETF Trust	7,426,282	0	0	For
CAPITAL ADVISORS INC/OK	231,592	0	0	For
Natixis	89,596	399	0	For
ROCKEFELLER FINANCIAL LLC	76,753	0	0	For
Jackson National	43,484	24,948	0	For
Carnegie Investment Counsel	67,340	0	0	For
ADVISORS SERIES TRUST	17,310	0	0	For
Loomis Sayles	9,378	0	0	For
BOSTON FAMILY OFFICE LLC	0	0	9,350	Abstain
Allianz	0	6,152	0	Against
John Hancock	91	3,838	0	Against
AMG Funds I	0	3,641	0	Against
DEARBORN PARTNERS LLC	3,550	0	0	For
RAYMOND JAMES & ASSOCIATES	0	2,689	0	Against
EA Series Trust	1,994	0	0	For
MERCER GLOBAL ADVISORS INC /ADV	1,735	0	0	For
WESTWOOD HOLDINGS GROUP INC	0	1,461	0	Against
Clear Harbor Asset Management, LLC	1,343	0	0	For
JPMorgan	1,297	0	0	For
Jacob Funds Inc.	1,203	0	0	For
RWA WEALTH PARTNERS, LLC	1,150	0	0	For
COBBLESTONE CAPITAL ADVISORS LLC /NY/	1,027	0	0	For
SPIREPOINT PRIVATE CLIENT, LLC	1,000	0	0	For
TRUST FOR PROFESSIONAL MANAGERS	0	914	0	Against
SCHAPER BENZ & WISE INVESTMENT COUNSEL INC/WI	860	0	0	For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

4. Approval of amendments to the Articles of Association to facilitate the use of equity compensation and pension benefits programs consistent with current market practices.

COMPENSATIONCORPORATE GOVERNANCE

Meeting held 2024-05-30.

Combines 6 wordings of this item as funds reported it.

97% fund support · no official result

FOR 97%

The 67 asset managers below cast 97% of the shares they voted on this item FOR (17,340,663 for, 605,762 against).

FOR: 17,340,663 (96.6%)AGAINST: 605,762 (3.4%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Approval of amendments to the Articles of Association to facilitate the use of equity compensation and pension” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
ARK ETF Trust	7,426,282	0	For
Capital Group	6,194,677	0	For
T. Rowe Price	1,445,748	42,642	For
Vanguard	874,759	0	For
Charles Schwab	669,580	0	For
BlackRock	0	234,394	Against
Fidelity	104,519	38,112	For
Equitable	124,294	1,170	For
State Street	107,434	0	For
Natixis	89,596	0	For
Global X	75,358	0	For
Lincoln Financial	71,808	0	For
Jackson National	43,484	24,948	For
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	0	29,503	Against
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
Capitol Series Trust	18,000	0	For
ADVISORS SERIES TRUST	17,310	0	For
American Century	0	15,793	Against
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
AMERICAN BEACON FUNDS	11,871	0	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

5. Approval of an amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.

COMPENSATION

Meeting held 2024-05-30.

Combines 5 wordings of this item as funds reported it.

98% fund support · no official result

FOR 97%

The 66 asset managers below cast 98% of the shares they voted on this item FOR (17,501,584 for, 440,652 against).

FOR: 17,501,584 (97.5%)AGAINST: 440,652 (2.5%)ABSTAIN: 10,500 (0.1%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Approval of an amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
ARK ETF Trust	7,426,282	0	For
Capital Group	6,194,677	0	For
T. Rowe Price	1,445,748	42,642	For
Vanguard	874,759	0	For
Charles Schwab	669,580	0	For
BlackRock	234,394	0	For
Fidelity	142,631	0	For
Equitable	124,294	1,170	For
State Street	0	107,434	Against
Natixis	89,596	0	For
Global X	75,358	0	For
Lincoln Financial	71,808	0	For
Jackson National	43,484	24,948	For
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	0	29,503	Against
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
Capitol Series Trust	18,000	0	For
ADVISORS SERIES TRUST	17,310	0	For
American Century	0	15,793	Against
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
AMERICAN BEACON FUNDS	11,871	0	For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

6. Approval of an increase of the conditional share capital for employee equity plans.

CAPITAL STRUCTURE

Meeting held 2024-05-30.

Combines 6 wordings of this item as funds reported it.

93% fund support · no official result

FOR 93%

The 64 asset managers below cast 93% of the shares they voted on this item FOR (16,731,463 for, 1,214,603 against).

FOR: 16,731,463 (93.2%)AGAINST: 1,214,603 (6.8%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Approval of an increase of the conditional share capital for employee equity plans.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
ARK ETF Trust	7,426,282	0	For
Capital Group	6,194,677	0	For
T. Rowe Price	1,445,748	42,642	For
Vanguard	874,759	0	For
Charles Schwab	0	669,580	Against
BlackRock	234,394	0	For
Fidelity	142,631	0	For
Equitable	124,294	1,170	For
State Street	0	107,434	Against
Natixis	89,596	0	For
Global X	0	75,358	Against
Lincoln Financial	71,808	0	For
Jackson National	43,484	24,948	For
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	0	29,503	Against
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
Capitol Series Trust	0	18,000	Against
ADVISORS SERIES TRUST	17,310	0	For
American Century	0	15,793	Against
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
AMERICAN BEACON FUNDS	11,871	0	For

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

7. Approval of an increase and certain adjustments to the Company's capital band.

CAPITAL STRUCTURE

Meeting held 2024-05-30.

Combines 6 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 63 asset managers below cast 99.9% of the shares they voted on this item FOR (17,944,998 for, 468 against).

FOR: 17,944,998 (100.0%)AGAINST: 468 (0.0%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Approval of an increase and certain adjustments to the Company's capital band.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Vote
ARK ETF Trust	7,426,282	For
Capital Group	6,194,677	For
T. Rowe Price	1,488,390	For
Vanguard	874,759	For
Charles Schwab	669,580	For
BlackRock	234,394	For
Fidelity	142,631	For
Equitable	125,464	For
State Street	107,434	For
Natixis	89,596	For
Global X	75,358	For
Lincoln Financial	71,808	For
Jackson National	68,432	For
Allspring	59,074	For
Direxion Shares ETF Trust	30,040	For
Nushares ETF Trust	29,503	For
RMB INVESTORS TRUST	29,295	For
Guggenheim	26,467	For
ProShares	22,917	For
Capitol Series Trust	18,000	For
ADVISORS SERIES TRUST	17,310	For
American Century	15,793	For
Northwestern Mutual	14,200	For
EXCHANGE TRADED CONCEPTS TRUST	11,979	For
AMERICAN BEACON FUNDS	11,871	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

8. Approval of the Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2023.

OTHER

Meeting held 2024-05-30.

Combines 5 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 63 asset managers below cast 100% of the shares they voted on this item FOR (17,945,466 for, 0 against).

FOR: 17,945,466 (100.0%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Approval of the Swiss management report, the consolidated financial statements and the statutory financial sta” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Vote
ARK ETF Trust	7,426,282	For
Capital Group	6,194,677	For
T. Rowe Price	1,488,390	For
Vanguard	874,759	For
Charles Schwab	669,580	For
BlackRock	234,394	For
Fidelity	142,631	For
Equitable	125,464	For
State Street	107,434	For
Natixis	89,596	For
Global X	75,358	For
Lincoln Financial	71,808	For
Jackson National	68,432	For
Allspring	59,074	For
Direxion Shares ETF Trust	30,040	For
Nushares ETF Trust	29,503	For
RMB INVESTORS TRUST	29,295	For
Guggenheim	26,467	For
ProShares	22,917	For
Capitol Series Trust	18,000	For
ADVISORS SERIES TRUST	17,310	For
American Century	15,793	For
Northwestern Mutual	14,200	For
EXCHANGE TRADED CONCEPTS TRUST	11,979	For
AMERICAN BEACON FUNDS	11,871	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

9. Approval of the appropriation of financial results.

CAPITAL STRUCTUREOTHER

Meeting held 2024-05-30.

Combines 5 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 63 asset managers below cast 100% of the shares they voted on this item FOR (17,945,466 for, 0 against).

FOR: 17,945,466 (100.0%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Approval of the appropriation of financial results.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Vote
ARK ETF Trust	7,426,282	For
Capital Group	6,194,677	For
T. Rowe Price	1,488,390	For
Vanguard	874,759	For
Charles Schwab	669,580	For
BlackRock	234,394	For
Fidelity	142,631	For
Equitable	125,464	For
State Street	107,434	For
Natixis	89,596	For
Global X	75,358	For
Lincoln Financial	71,808	For
Jackson National	68,432	For
Allspring	59,074	For
Direxion Shares ETF Trust	30,040	For
Nushares ETF Trust	29,503	For
RMB INVESTORS TRUST	29,295	For
Guggenheim	26,467	For
ProShares	22,917	For
Capitol Series Trust	18,000	For
ADVISORS SERIES TRUST	17,310	For
American Century	15,793	For
Northwestern Mutual	14,200	For
EXCHANGE TRADED CONCEPTS TRUST	11,979	For
AMERICAN BEACON FUNDS	11,871	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

10. Discharge of the members of the Board of Directors and the Executive Committee.

CORPORATE GOVERNANCE

Meeting held 2024-05-30.

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 63 asset managers below cast 100% of the shares they voted on this item FOR (17,945,466 for, 0 against).

FOR: 17,945,466 (100.0%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Discharge of the members of the Board of Directors and the Executive Committee.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Vote
ARK ETF Trust	7,426,282	For
Capital Group	6,194,677	For
T. Rowe Price	1,488,390	For
Vanguard	874,759	For
Charles Schwab	669,580	For
BlackRock	234,394	For
Fidelity	142,631	For
Equitable	125,464	For
State Street	107,434	For
Natixis	89,596	For
Global X	75,358	For
Lincoln Financial	71,808	For
Jackson National	68,432	For
Allspring	59,074	For
Direxion Shares ETF Trust	30,040	For
Nushares ETF Trust	29,503	For
RMB INVESTORS TRUST	29,295	For
Guggenheim	26,467	For
ProShares	22,917	For
Capitol Series Trust	18,000	For
ADVISORS SERIES TRUST	17,310	For
American Century	15,793	For
Northwestern Mutual	14,200	For
EXCHANGE TRADED CONCEPTS TRUST	11,979	For
AMERICAN BEACON FUNDS	11,871	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

11. Election or re-election of the members to the Board of Directors and the Chairman: Election of Christian Rommel, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-05-30.

Combines 5 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 42,777,061AGAINST: 162,398

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Christian Rommel, Ph.D.”): 42,777,061 for, 162,398 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 84,837,610 outstanding shares: 50.4% for, 0.2% against (50.6% of the company cast a for/against vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (17,945,466 for, 0 against).

FOR 99.9%

FOR: 17,945,466 (100.0%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Election of Christian Romme” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Vote
ARK ETF Trust	7,426,282	For
Capital Group	6,194,677	For
T. Rowe Price	1,488,390	For
Vanguard	874,759	For
Charles Schwab	669,580	For
BlackRock	234,394	For
Fidelity	142,631	For
Equitable	125,464	For
State Street	107,434	For
Natixis	89,596	For
Global X	75,358	For
Lincoln Financial	71,808	For
Jackson National	68,432	For
Allspring	59,074	For
Direxion Shares ETF Trust	30,040	For
Nushares ETF Trust	29,503	For
RMB INVESTORS TRUST	29,295	For
Guggenheim	26,467	For
ProShares	22,917	For
Capitol Series Trust	18,000	For
ADVISORS SERIES TRUST	17,310	For
American Century	15,793	For
Northwestern Mutual	14,200	For
EXCHANGE TRADED CONCEPTS TRUST	11,979	For
AMERICAN BEACON FUNDS	11,871	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

12. Election or re-election of the members to the Board of Directors and the Chairman: Election of Sandesh Mahatme, LL.M.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-05-30.

Combines 5 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%

FOR: 42,762,070AGAINST: 177,633

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Sandesh Mahatme, LL.M.”): 42,762,070 for, 177,633 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 84,837,610 outstanding shares: 50.4% for, 0.3% against (50.6% of the company cast a for/against vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (17,945,466 for, 0 against).

FOR 99.9%

FOR: 17,945,466 (100.0%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Election of Sandesh Mahatme” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Vote
ARK ETF Trust	7,426,282	For
Capital Group	6,194,677	For
T. Rowe Price	1,488,390	For
Vanguard	874,759	For
Charles Schwab	669,580	For
BlackRock	234,394	For
Fidelity	142,631	For
Equitable	125,464	For
State Street	107,434	For
Natixis	89,596	For
Global X	75,358	For
Lincoln Financial	71,808	For
Jackson National	68,432	For
Allspring	59,074	For
Direxion Shares ETF Trust	30,040	For
Nushares ETF Trust	29,503	For
RMB INVESTORS TRUST	29,295	For
Guggenheim	26,467	For
ProShares	22,917	For
Capitol Series Trust	18,000	For
ADVISORS SERIES TRUST	17,310	For
American Century	15,793	For
Northwestern Mutual	14,200	For
EXCHANGE TRADED CONCEPTS TRUST	11,979	For
AMERICAN BEACON FUNDS	11,871	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

13. Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Douglas A. Treco, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-05-30.

Combines 6 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 40,807,871AGAINST: 2,133,551

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Douglas A. Treco, Ph.D.”): 40,807,871 for, 2,133,551 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 84,837,610 outstanding shares: 48.1% for, 3% against (50.6% of the company cast a for/against vote).

The 63 asset managers below cast 98% of the shares they voted on this item FOR (17,672,491 for, 272,975 against).

FOR 98%

FOR: 17,672,491 (98.5%)AGAINST: 272,975 (1.5%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Douglas A. T” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
ARK ETF Trust	7,426,282	0	For
Capital Group	6,194,677	0	For
T. Rowe Price	1,488,390	0	For
Vanguard	874,759	0	For
Charles Schwab	669,580	0	For
BlackRock	0	234,394	Against
Fidelity	104,519	38,112	For
Equitable	125,464	0	For
State Street	107,434	0	For
Natixis	89,596	0	For
Global X	75,358	0	For
Lincoln Financial	71,808	0	For
Jackson National	68,432	0	For
Allspring	59,074	0	For
Direxion Shares ETF Trust	30,040	0	For
Nushares ETF Trust	29,503	0	For
RMB INVESTORS TRUST	29,295	0	For
Guggenheim	26,467	0	For
ProShares	22,917	0	For
Capitol Series Trust	18,000	0	For
ADVISORS SERIES TRUST	17,310	0	For
American Century	15,793	0	For
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	11,979	0	For
AMERICAN BEACON FUNDS	11,871	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

14. Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Katherine A. High, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-05-30.

Combines 6 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%

FOR: 42,672,595AGAINST: 274,928

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Katherine A. High, M.D.”): 42,672,595 for, 274,928 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 84,837,610 outstanding shares: 50.3% for, 0.4% against (50.6% of the company cast a for/against vote).

The 63 asset managers below cast 99.9% of the shares they voted on this item FOR (17,944,998 for, 468 against).

FOR 99.9%

FOR: 17,944,998 (100.0%)AGAINST: 468 (0.0%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Katherine A.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Vote
ARK ETF Trust	7,426,282	For
Capital Group	6,194,677	For
T. Rowe Price	1,488,390	For
Vanguard	874,759	For
Charles Schwab	669,580	For
BlackRock	234,394	For
Fidelity	142,631	For
Equitable	125,464	For
State Street	107,434	For
Natixis	89,596	For
Global X	75,358	For
Lincoln Financial	71,808	For
Jackson National	68,432	For
Allspring	59,074	For
Direxion Shares ETF Trust	30,040	For
Nushares ETF Trust	29,503	For
RMB INVESTORS TRUST	29,295	For
Guggenheim	26,467	For
ProShares	22,917	For
Capitol Series Trust	18,000	For
ADVISORS SERIES TRUST	17,310	For
American Century	15,793	For
Northwestern Mutual	14,200	For
EXCHANGE TRADED CONCEPTS TRUST	11,979	For
AMERICAN BEACON FUNDS	11,871	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

15. Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Maria Fardis, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-05-30.

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 42,253,383AGAINST: 689,281

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Maria Fardis, Ph.D.”): 42,253,383 for, 689,281 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 84,837,610 outstanding shares: 49.8% for, 0.9% against (50.6% of the company cast a for/against vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (17,945,466 for, 0 against).

FOR 99.9%

FOR: 17,945,466 (100.0%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Maria Fardis” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Vote
ARK ETF Trust	7,426,282	For
Capital Group	6,194,677	For
T. Rowe Price	1,488,390	For
Vanguard	874,759	For
Charles Schwab	669,580	For
BlackRock	234,394	For
Fidelity	142,631	For
Equitable	125,464	For
State Street	107,434	For
Natixis	89,596	For
Global X	75,358	For
Lincoln Financial	71,808	For
Jackson National	68,432	For
Allspring	59,074	For
Direxion Shares ETF Trust	30,040	For
Nushares ETF Trust	29,503	For
RMB INVESTORS TRUST	29,295	For
Guggenheim	26,467	For
ProShares	22,917	For
Capitol Series Trust	18,000	For
ADVISORS SERIES TRUST	17,310	For
American Century	15,793	For
Northwestern Mutual	14,200	For
EXCHANGE TRADED CONCEPTS TRUST	11,979	For
AMERICAN BEACON FUNDS	11,871	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

16. Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Samarth Kulkarni, Ph.D., as member and election as Chairman

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-05-30.

Combines 7 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 42,442,977AGAINST: 503,265

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Samarth Kulkarni, Ph.D.”): 42,442,977 for, 503,265 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 84,837,610 outstanding shares: 50.1% for, 0.6% against (50.6% of the company cast a for/against vote).

The 63 asset managers below cast 99.9% of the shares they voted on this item FOR (17,945,346 for, 120 against).

FOR 99.9%

FOR: 17,945,346 (100.0%)AGAINST: 120 (0.0%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Samarth Kulk” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Vote
ARK ETF Trust	7,426,282	For
Capital Group	6,194,677	For
T. Rowe Price	1,488,390	For
Vanguard	874,759	For
Charles Schwab	669,580	For
BlackRock	234,394	For
Fidelity	142,631	For
Equitable	125,464	For
State Street	107,434	For
Natixis	89,596	For
Global X	75,358	For
Lincoln Financial	71,808	For
Jackson National	68,432	For
Allspring	59,074	For
Direxion Shares ETF Trust	30,040	For
Nushares ETF Trust	29,503	For
RMB INVESTORS TRUST	29,295	For
Guggenheim	26,467	For
ProShares	22,917	For
Capitol Series Trust	18,000	For
ADVISORS SERIES TRUST	17,310	For
American Century	15,793	For
Northwestern Mutual	14,200	For
EXCHANGE TRADED CONCEPTS TRUST	11,979	For
AMERICAN BEACON FUNDS	11,871	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

17. Re-election of the auditors.

AUDIT-RELATED

Meeting held 2024-05-30.

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.8%

The 63 asset managers below cast 99.9% of the shares they voted on this item FOR (17,926,884 for, 582 against).

FOR: 17,926,884 (99.9%)AGAINST: 582 (0.0%)ABSTAIN: 18,000 (0.1%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Re-election of the auditors.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Abstain	Vote
ARK ETF Trust	7,426,282	0	For
Capital Group	6,194,677	0	For
T. Rowe Price	1,488,390	0	For
Vanguard	874,759	0	For
Charles Schwab	669,580	0	For
BlackRock	234,394	0	For
Fidelity	142,631	0	For
Equitable	125,464	0	For
State Street	107,434	0	For
Natixis	89,596	0	For
Global X	75,358	0	For
Lincoln Financial	71,808	0	For
Jackson National	68,432	0	For
Allspring	59,074	0	For
Direxion Shares ETF Trust	30,040	0	For
Nushares ETF Trust	29,503	0	For
RMB INVESTORS TRUST	29,295	0	For
Guggenheim	26,467	0	For
ProShares	22,917	0	For
Capitol Series Trust	0	18,000	Abstain
ADVISORS SERIES TRUST	17,310	0	For
American Century	15,793	0	For
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	11,979	0	For
AMERICAN BEACON FUNDS	11,871	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

18. Re-election of the independent voting rights representative.

CORPORATE GOVERNANCE

Meeting held 2024-05-30.

Combines 5 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 63 asset managers below cast 100% of the shares they voted on this item FOR (17,945,466 for, 0 against).

FOR: 17,945,466 (100.0%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Re-election of the independent voting rights representative.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Vote
ARK ETF Trust	7,426,282	For
Capital Group	6,194,677	For
T. Rowe Price	1,488,390	For
Vanguard	874,759	For
Charles Schwab	669,580	For
BlackRock	234,394	For
Fidelity	142,631	For
Equitable	125,464	For
State Street	107,434	For
Natixis	89,596	For
Global X	75,358	For
Lincoln Financial	71,808	For
Jackson National	68,432	For
Allspring	59,074	For
Direxion Shares ETF Trust	30,040	For
Nushares ETF Trust	29,503	For
RMB INVESTORS TRUST	29,295	For
Guggenheim	26,467	For
ProShares	22,917	For
Capitol Series Trust	18,000	For
ADVISORS SERIES TRUST	17,310	For
American Century	15,793	For
Northwestern Mutual	14,200	For
EXCHANGE TRADED CONCEPTS TRUST	11,979	For
AMERICAN BEACON FUNDS	11,871	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

19. Transact any other business that may properly come before the 2024 Annual General Meeting or any adjournment or postponement thereof.

OTHER

Meeting held 2024-05-30.

Combines 5 wordings of this item as funds reported it.

42% fund support · no official result

FOR 42%AGAINST 58%

The 63 asset managers below cast 42% of the shares they voted on this item FOR (7,506,993 for, 10,436,479 against).

FOR: 7,506,993 (41.8%)AGAINST: 10,436,479 (58.2%)ABSTAIN: 1,994 (0.0%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Transact any other business that may properly come before the 2024 Annual General Meeting or any adjournment o” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
ARK ETF Trust	7,426,282	0	For
Capital Group	0	6,194,677	Against
T. Rowe Price	0	1,488,390	Against
Vanguard	0	874,759	Against
Charles Schwab	0	669,580	Against
BlackRock	0	234,394	Against
Fidelity	0	142,631	Against
Equitable	0	125,464	Against
State Street	0	107,434	Against
Natixis	0	89,596	Against
Global X	0	75,358	Against
Lincoln Financial	0	71,808	Against
Jackson National	34,162	34,270	Against
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	0	29,503	Against
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
Capitol Series Trust	0	18,000	Against
ADVISORS SERIES TRUST	17,310	0	For
American Century	0	15,793	Against
Northwestern Mutual	0	14,200	Against
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
AMERICAN BEACON FUNDS	11,871	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

20. Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2024.

COMPENSATION

Meeting held 2024-05-30.

Combines 8 wordings of this item as funds reported it.

96% fund support · no official result

FOR 96%

The 60 asset managers below cast 96% of the shares they voted on this item FOR (12,758,591 for, 512,060 against).

FOR: 12,758,591 (96.1%)AGAINST: 512,060 (3.9%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Binding vote on maximum variable compensation for members of the Executive Committee for the current year endi” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
Capital Group	6,194,677	0	For
T. Rowe Price	1,445,748	42,642	For
EcoR1 Capital, LLC	1,389,276	0	For
SR ONE CAPITAL MANAGEMENT, LP	1,048,951	0	For
Vanguard	874,759	0	For
Charles Schwab	669,580	0	For
Versant Venture Management, LLC	500,028	0	For
BlackRock	234,394	0	For
Fidelity	38,112	104,519	Against
Equitable	124,294	1,170	For
State Street	0	107,434	Against
Global X	75,358	0	For
Lincoln Financial	71,808	0	For
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	0	29,503	Against
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
Capitol Series Trust	18,000	0	For
American Century	0	15,793	Against
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
AMERICAN BEACON FUNDS	11,871	0	For
Listed Funds Trust	0	10,557	Against

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

21. Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July 1, 2024 to June 30, 2025.

COMPENSATION

Meeting held 2024-05-30.

Combines 8 wordings of this item as funds reported it.

96% fund support · no official result

FOR 96%

The 59 asset managers below cast 96% of the shares they voted on this item FOR (11,369,250 for, 512,060 against).

FOR: 11,369,250 (95.7%)AGAINST: 512,060 (4.3%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
Capital Group	6,194,677	0	For
T. Rowe Price	1,445,748	42,642	For
SR ONE CAPITAL MANAGEMENT, LP	1,048,951	0	For
Vanguard	874,759	0	For
Charles Schwab	669,580	0	For
Versant Venture Management, LLC	500,028	0	For
BlackRock	234,394	0	For
Fidelity	38,112	104,519	Against
Equitable	124,294	1,170	For
State Street	0	107,434	Against
Global X	75,358	0	For
Lincoln Financial	71,808	0	For
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	0	29,503	Against
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
Capitol Series Trust	18,000	0	For
American Century	0	15,793	Against
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
AMERICAN BEACON FUNDS	11,871	0	For
Listed Funds Trust	0	10,557	Against
Goldman Sachs	0	10,005	Against

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

22. Binding vote on maximum equity for members of the Executive Committee from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders.

COMPENSATION

Meeting held 2024-05-30.

Combines 7 wordings of this item as funds reported it.

87% fund support · no official result

FOR 87%13%

The 55 asset managers below cast 87% of the shares they voted on this item FOR (10,316,284 for, 1,560,532 against).

FOR: 10,316,284 (86.8%)AGAINST: 1,560,532 (13.1%)ABSTAIN: 4,000 (0.0%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Binding vote on maximum equity for members of the Executive Committee from the 2024 Annual General Meeting to ” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
Capital Group	6,194,677	0	For
T. Rowe Price	1,445,748	42,642	For
SR ONE CAPITAL MANAGEMENT, LP	1,048,951	0	For
Vanguard	874,759	0	For
Charles Schwab	0	669,580	Against
Versant Venture Management, LLC	500,028	0	For
BlackRock	0	234,394	Against
Fidelity	0	142,631	Against
Equitable	124,294	1,170	For
State Street	0	107,434	Against
Global X	0	75,358	Against
Lincoln Financial	71,808	0	For
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	0	29,503	Against
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
Capitol Series Trust	0	18,000	Against
American Century	0	15,793	Against
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
AMERICAN BEACON FUNDS	11,871	0	For
Listed Funds Trust	0	10,557	Against
Goldman Sachs	0	10,005	Against

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

23. Binding vote on maximum equity for members of the Board of Directors from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders.

COMPENSATION

Meeting held 2024-05-30.

Combines 7 wordings of this item as funds reported it.

88% fund support · no official result

FOR 88%12%

The 53 asset managers below cast 88% of the shares they voted on this item FOR (10,497,038 for, 1,379,611 against).

FOR: 10,497,038 (88.3%)AGAINST: 1,379,611 (11.6%)ABSTAIN: 4,000 (0.0%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Binding vote on maximum equity for members of the Board of Directors from the 2024 Annual General Meeting to t” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
Capital Group	6,194,677	0	For
T. Rowe Price	1,445,748	42,642	For
SR ONE CAPITAL MANAGEMENT, LP	1,048,951	0	For
Vanguard	874,759	0	For
Charles Schwab	0	669,580	Against
Versant Venture Management, LLC	500,028	0	For
BlackRock	234,394	0	For
Fidelity	142,631	0	For
Equitable	0	125,464	Against
State Street	0	107,434	Against
Global X	0	75,358	Against
Lincoln Financial	0	71,808	Against
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	0	29,503	Against
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
Capitol Series Trust	0	18,000	Against
American Century	0	15,793	Against
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
AMERICAN BEACON FUNDS	11,871	0	For
Listed Funds Trust	0	10,557	Against
Goldman Sachs	0	10,005	Against

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

24. Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2023 Compensation Report: Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders.

COMPENSATION

Meeting held 2024-05-30.

100% fund support · no official result

FOR 100%

The 49 asset managers below cast 100% of the shares they voted on this item FOR (17,128,556 for, 0 against).

FOR: 17,128,556 (100.0%)

Largest asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Vote
ARK ETF Trust	7,426,282	For
Capital Group	6,194,677	For
T. Rowe Price	1,488,390	For
Vanguard	874,759	For
BlackRock	234,394	For
Fidelity	142,631	For
Equitable	125,464	For
State Street	107,434	For
Natixis	89,596	For
Lincoln Financial	71,808	For
Jackson National	68,432	For
Allspring	59,074	For
Direxion Shares ETF Trust	30,040	For
Nushares ETF Trust	29,503	For
RMB INVESTORS TRUST	29,295	For
Guggenheim	26,467	For
ProShares	22,917	For
ADVISORS SERIES TRUST	17,310	For
American Century	15,793	For
Northwestern Mutual	14,200	For
EXCHANGE TRADED CONCEPTS TRUST	11,979	For
Goldman Sachs	10,005	For
Loomis Sayles	9,378	For
Allianz	6,152	For
John Hancock	3,929	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

25. Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Ali Behbahani, M.D.

DIRECTOR ELECTIONS

Meeting held 2024-05-30.

Combines 2 wordings of this item as funds reported it.

65% fund support · no official result

FOR 65%AGAINST 35%

The 36 asset managers below cast 65% of the shares they voted on this item FOR (6,194,677 for, 3,313,394 against).

FOR: 6,194,677 (65.2%)AGAINST: 3,313,394 (34.8%)

Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Ali Behbahan” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
Capital Group	6,194,677	0	For
T. Rowe Price	0	1,488,390	Against
Vanguard	0	874,759	Against
BlackRock	0	234,394	Against
Fidelity	0	142,631	Against
Equitable	0	125,464	Against
State Street	0	107,434	Against
Lincoln Financial	0	71,808	Against
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	0	29,503	Against
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
American Century	0	15,793	Against
Northwestern Mutual	0	14,200	Against
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
Listed Funds Trust	0	10,557	Against
Goldman Sachs	0	10,005	Against
MassMutual	0	1,338	Against
ETFis Series Trust I	0	1,321	Against
Franklin Templeton	0	1,305	Against
First Trust	0	1,231	Against
AQR	0	1,146	Against
Empower	0	597	Against

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

26. Election or re-election of the members to the Board of Directors and the Chairman: Re-election of H. Edward Fleming, Jr., M.D.

DIRECTOR ELECTIONS

Meeting held 2024-05-30.

Combines 2 wordings of this item as funds reported it.

97% fund support · no official result

FOR 97%

The 36 asset managers below cast 97% of the shares they voted on this item FOR (9,191,116 for, 316,955 against).

FOR: 9,191,116 (96.7%)AGAINST: 316,955 (3.3%)

Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of H. Edward Fl” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
Capital Group	6,194,677	0	For
T. Rowe Price	1,488,390	0	For
Vanguard	874,759	0	For
BlackRock	234,394	0	For
Fidelity	38,112	104,519	Against
Equitable	125,464	0	For
State Street	107,434	0	For
Lincoln Financial	71,808	0	For
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	29,503	0	For
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
American Century	0	15,793	Against
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
Listed Funds Trust	0	10,557	Against
Goldman Sachs	10,005	0	For
MassMutual	1,338	0	For
ETFis Series Trust I	0	1,321	Against
Franklin Templeton	0	1,305	Against
First Trust	0	1,231	Against
AQR	0	1,146	Against
Empower	597	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

27. Election or re-election of the members to the Board of Directors and the Chairman: Re-election of John T. Greene

DIRECTOR ELECTIONS

Meeting held 2024-05-30.

Combines 2 wordings of this item as funds reported it.

97% fund support · no official result

FOR 97%

The 36 asset managers below cast 97% of the shares they voted on this item FOR (9,191,489 for, 316,582 against).

FOR: 9,191,489 (96.7%)AGAINST: 316,582 (3.3%)

Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of John T. Gree” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
Capital Group	6,194,677	0	For
T. Rowe Price	1,488,390	0	For
Vanguard	874,759	0	For
BlackRock	234,394	0	For
Fidelity	38,112	104,519	Against
Equitable	125,464	0	For
State Street	107,434	0	For
Lincoln Financial	71,808	0	For
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	29,503	0	For
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
American Century	0	15,793	Against
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
Listed Funds Trust	0	10,557	Against
Goldman Sachs	10,005	0	For
MassMutual	1,338	0	For
ETFis Series Trust I	0	1,321	Against
Franklin Templeton	0	1,305	Against
First Trust	0	1,231	Against
AQR	0	1,146	Against
Empower	597	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

28. Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Simeon J. George, M.D.

DIRECTOR ELECTIONS

Meeting held 2024-05-30.

Combines 2 wordings of this item as funds reported it.

94% fund support · no official result

FOR 94%

The 36 asset managers below cast 94% of the shares they voted on this item FOR (8,918,983 for, 589,088 against).

FOR: 8,918,983 (93.8%)AGAINST: 589,088 (6.2%)

Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Simeon J. Ge” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
Capital Group	6,194,677	0	For
T. Rowe Price	1,488,390	0	For
Vanguard	874,759	0	For
BlackRock	0	234,394	Against
Fidelity	0	142,631	Against
Equitable	125,464	0	For
State Street	107,434	0	For
Lincoln Financial	71,808	0	For
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	29,503	0	For
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
American Century	0	15,793	Against
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
Listed Funds Trust	0	10,557	Against
Goldman Sachs	10,005	0	For
MassMutual	1,338	0	For
ETFis Series Trust I	0	1,321	Against
Franklin Templeton	0	1,305	Against
First Trust	0	1,231	Against
AQR	0	1,146	Against
Empower	597	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

29. Re-election of the members of the Compensation Committee: Re-election of Ali Behbahani, M.D.

DIRECTOR ELECTIONSCORPORATE GOVERNANCE

Meeting held 2024-05-30.

Combines 2 wordings of this item as funds reported it.

65% fund support · no official result

FOR 65%AGAINST 35%

The 36 asset managers below cast 65% of the shares they voted on this item FOR (6,194,677 for, 3,313,394 against).

FOR: 6,194,677 (65.2%)AGAINST: 3,313,394 (34.8%)

Largest asset managers voting on “Re-election of the members of the Compensation Committee: Re-election of Ali Behbahani, M.D.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
Capital Group	6,194,677	0	For
T. Rowe Price	0	1,488,390	Against
Vanguard	0	874,759	Against
BlackRock	0	234,394	Against
Fidelity	0	142,631	Against
Equitable	0	125,464	Against
State Street	0	107,434	Against
Lincoln Financial	0	71,808	Against
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	0	29,503	Against
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
American Century	0	15,793	Against
Northwestern Mutual	0	14,200	Against
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
Listed Funds Trust	0	10,557	Against
Goldman Sachs	0	10,005	Against
MassMutual	0	1,338	Against
ETFis Series Trust I	0	1,321	Against
Franklin Templeton	0	1,305	Against
First Trust	0	1,231	Against
AQR	0	1,146	Against
Empower	0	597	Against

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

30. Re-election of the members of the Compensation Committee: Re-election of H. Edward Fleming, Jr., M.D.

DIRECTOR ELECTIONSCORPORATE GOVERNANCE

Meeting held 2024-05-30.

Combines 2 wordings of this item as funds reported it.

96% fund support · no official result

FOR 96%

The 36 asset managers below cast 96% of the shares they voted on this item FOR (9,146,953 for, 361,118 against).

FOR: 9,146,953 (96.2%)AGAINST: 361,118 (3.8%)

Largest asset managers voting on “Re-election of the members of the Compensation Committee: Re-election of H. Edward Fleming, Jr., M.D.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
Capital Group	6,194,677	0	For
T. Rowe Price	1,445,748	42,642	For
Vanguard	874,759	0	For
BlackRock	234,394	0	For
Fidelity	38,112	104,519	Against
Equitable	124,294	1,170	For
State Street	107,434	0	For
Lincoln Financial	71,808	0	For
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	29,503	0	For
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
American Century	0	15,793	Against
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
Listed Funds Trust	0	10,557	Against
Goldman Sachs	10,005	0	For
MassMutual	1,338	0	For
ETFis Series Trust I	0	1,321	Against
Franklin Templeton	0	1,305	Against
First Trust	0	1,231	Against
AQR	0	1,146	Against
Empower	597	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

31. Re-election of the members of the Compensation Committee: Re-election of John T. Greene

DIRECTOR ELECTIONSCORPORATE GOVERNANCE

Meeting held 2024-05-30.

Combines 2 wordings of this item as funds reported it.

96% fund support · no official result

FOR 96%

The 36 asset managers below cast 96% of the shares they voted on this item FOR (9,147,326 for, 360,745 against).

FOR: 9,147,326 (96.2%)AGAINST: 360,745 (3.8%)

Largest asset managers voting on “Re-election of the members of the Compensation Committee: Re-election of John T. Greene” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
Capital Group	6,194,677	0	For
T. Rowe Price	1,445,748	42,642	For
Vanguard	874,759	0	For
BlackRock	234,394	0	For
Fidelity	38,112	104,519	Against
Equitable	124,294	1,170	For
State Street	107,434	0	For
Lincoln Financial	71,808	0	For
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	29,503	0	For
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
American Century	0	15,793	Against
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
Listed Funds Trust	0	10,557	Against
Goldman Sachs	10,005	0	For
MassMutual	1,338	0	For
ETFis Series Trust I	0	1,321	Against
Franklin Templeton	0	1,305	Against
First Trust	0	1,231	Against
AQR	0	1,146	Against
Empower	597	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

32. Re-election of the members of the Compensation Committee: Re-election of Simeon J. George, M.D.

DIRECTOR ELECTIONSCORPORATE GOVERNANCE

Meeting held 2024-05-30.

Combines 2 wordings of this item as funds reported it.

93% fund support · no official result

FOR 93%

The 36 asset managers below cast 93% of the shares they voted on this item FOR (8,874,820 for, 633,251 against).

FOR: 8,874,820 (93.3%)AGAINST: 633,251 (6.7%)

Largest asset managers voting on “Re-election of the members of the Compensation Committee: Re-election of Simeon J. George, M.D.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
Capital Group	6,194,677	0	For
T. Rowe Price	1,445,748	42,642	For
Vanguard	874,759	0	For
BlackRock	0	234,394	Against
Fidelity	0	142,631	Against
Equitable	124,294	1,170	For
State Street	107,434	0	For
Lincoln Financial	71,808	0	For
Allspring	0	59,074	Against
Direxion Shares ETF Trust	0	30,040	Against
Nushares ETF Trust	29,503	0	For
RMB INVESTORS TRUST	0	29,295	Against
Guggenheim	0	26,467	Against
ProShares	0	22,917	Against
American Century	0	15,793	Against
Northwestern Mutual	14,200	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	11,979	Against
Listed Funds Trust	0	10,557	Against
Goldman Sachs	10,005	0	For
MassMutual	1,338	0	For
ETFis Series Trust I	0	1,321	Against
Franklin Templeton	0	1,305	Against
First Trust	0	1,231	Against
AQR	0	1,146	Against
Empower	597	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

33. Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders.

COMPENSATION

Meeting held 2024-05-30.

Combines 6 wordings of this item as funds reported it.

99.8% fund support · no official result

FOR 99.7%

The 21 asset managers below cast 99.8% of the shares they voted on this item FOR (2,368,994 for, 4,000 against).

FOR: 2,368,994 (99.8%)AGAINST: 4,000 (0.2%)UNKNOWN: 1,000 (0.0%)

Largest asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
SR ONE CAPITAL MANAGEMENT, LP	1,048,951	0	For
Charles Schwab	669,580	0	For
Versant Venture Management, LLC	500,028	0	For
Global X	75,358	0	For
Capitol Series Trust	18,000	0	For
AMERICAN BEACON FUNDS	11,871	0	For
Janney Montgomery Scott LLC	9,562	0	For
Federated Hermes	8,840	0	For
Jasper Ridge Partners, L.P.	7,454	0	For
ARK Venture Fund	7,258	0	For
VanEck ETF Trust	6,998	0	For
WILLIAMSBURG INVESTMENT TRUST	0	4,000	Against
Collaborative Investment Series Trust	3,500	0	For
L. Roy Papp & Associates, LLP	0	0	Unknown
HOLLENCREST CAPITAL MANAGEMENT	600	0	For
Putnam	468	0	For
EXENCIAL WEALTH ADVISORS, LLC	318	0	For
HOWLAND CAPITAL MANAGEMENT LLC	110	0	For
Cannon Financial Strategists, Inc.	57	0	For
Belpointe Asset Management LLC	41	0	For
Opes Wealth Management LLC	0	0	--

34. Re-election of the members of the Compensation Committee: Ali Behbahani

CORPORATE GOVERNANCE

Meeting held 2024-05-30.

Combines 2 wordings of this item as funds reported it.

89% fund support · no official result

FOR 89%11%

The 21 asset managers below cast 89% of the shares they voted on this item FOR (7,489,911 for, 920,745 against).

FOR: 7,489,911 (89.1%)AGAINST: 920,745 (10.9%)

Largest asset managers voting on “Re-election of the members of the Compensation Committee: Ali Behbahani” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
ARK ETF Trust	7,426,282	0	For
Charles Schwab	0	669,580	Against
Natixis	0	89,596	Against
Global X	0	75,358	Against
Jackson National	34,162	34,270	Against
Capitol Series Trust	0	18,000	Against
ADVISORS SERIES TRUST	17,310	0	For
Loomis Sayles	0	9,378	Against
Federated Hermes	8,840	0	For
VanEck ETF Trust	0	6,998	Against
Allianz	0	6,152	Against
John Hancock	0	3,929	Against
AMG Funds I	0	3,641	Against
EA Series Trust	1,994	0	For
JPMorgan	0	1,297	Against
Jacob Funds Inc.	1,203	0	For
TRUST FOR PROFESSIONAL MANAGERS	0	914	Against
CITY NATIONAL ROCHDALE FUNDS	0	664	Against
Pacer Funds Trust	0	500	Against
Putnam	0	468	Against
Amplify ETF Trust	120	0	For

35. Re-election of the members of the Compensation Committee: H. Edward Fleming, Jr.

CORPORATE GOVERNANCE

Meeting held 2024-05-30.

Combines 2 wordings of this item as funds reported it.

92% fund support · no official result

FOR 92%8%

The 21 asset managers below cast 92% of the shares they voted on this item FOR (7,730,172 for, 680,484 against).

FOR: 7,730,172 (91.9%)AGAINST: 680,484 (8.1%)

Largest asset managers voting on “Re-election of the members of the Compensation Committee: H. Edward Fleming, Jr.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
ARK ETF Trust	7,426,282	0	For
Charles Schwab	0	669,580	Against
Natixis	89,596	0	For
Global X	75,358	0	For
Jackson National	68,432	0	For
Capitol Series Trust	18,000	0	For
ADVISORS SERIES TRUST	17,310	0	For
Loomis Sayles	9,378	0	For
Federated Hermes	8,840	0	For
VanEck ETF Trust	6,998	0	For
Allianz	0	6,152	Against
John Hancock	91	3,838	Against
AMG Funds I	3,641	0	For
EA Series Trust	1,994	0	For
JPMorgan	1,297	0	For
Jacob Funds Inc.	1,203	0	For
TRUST FOR PROFESSIONAL MANAGERS	0	914	Against
CITY NATIONAL ROCHDALE FUNDS	664	0	For
Pacer Funds Trust	500	0	For
Putnam	468	0	For
Amplify ETF Trust	120	0	For

36. Re-election of the members of the Compensation Committee: John T. Greene

CORPORATE GOVERNANCE

Meeting held 2024-05-30.

92% fund support · no official result

FOR 92%8%

The 21 asset managers below cast 92% of the shares they voted on this item FOR (7,730,172 for, 680,484 against).

FOR: 7,730,172 (91.9%)AGAINST: 680,484 (8.1%)

Largest asset managers voting on “Re-election of the members of the Compensation Committee: John T. Greene” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
ARK ETF Trust	7,426,282	0	For
Charles Schwab	0	669,580	Against
Natixis	89,596	0	For
Global X	75,358	0	For
Jackson National	68,432	0	For
Capitol Series Trust	18,000	0	For
ADVISORS SERIES TRUST	17,310	0	For
Loomis Sayles	9,378	0	For
Federated Hermes	8,840	0	For
VanEck ETF Trust	6,998	0	For
Allianz	0	6,152	Against
John Hancock	91	3,838	Against
AMG Funds I	3,641	0	For
EA Series Trust	1,994	0	For
JPMorgan	1,297	0	For
Jacob Funds Inc.	1,203	0	For
TRUST FOR PROFESSIONAL MANAGERS	0	914	Against
CITY NATIONAL ROCHDALE FUNDS	664	0	For
Pacer Funds Trust	500	0	For
Putnam	468	0	For
Amplify ETF Trust	120	0	For

37. Re-election of the members of the Compensation Committee: Simeon J. George

CORPORATE GOVERNANCE

Meeting held 2024-05-30.

Combines 2 wordings of this item as funds reported it.

91% fund support · no official result

FOR 91%9%

The 21 asset managers below cast 91% of the shares they voted on this item FOR (7,623,714 for, 786,942 against).

FOR: 7,623,714 (90.6%)AGAINST: 786,942 (9.4%)

Largest asset managers voting on “Re-election of the members of the Compensation Committee: Simeon J. George” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
ARK ETF Trust	7,426,282	0	For
Charles Schwab	0	669,580	Against
Natixis	89,596	0	For
Global X	0	75,358	Against
Jackson National	68,432	0	For
Capitol Series Trust	0	18,000	Against
ADVISORS SERIES TRUST	17,310	0	For
Loomis Sayles	9,378	0	For
Federated Hermes	8,840	0	For
VanEck ETF Trust	0	6,998	Against
Allianz	0	6,152	Against
John Hancock	91	3,838	Against
AMG Funds I	0	3,641	Against
EA Series Trust	1,994	0	For
JPMorgan	0	1,297	Against
Jacob Funds Inc.	1,203	0	For
TRUST FOR PROFESSIONAL MANAGERS	0	914	Against
CITY NATIONAL ROCHDALE FUNDS	0	664	Against
Pacer Funds Trust	0	500	Against
Putnam	468	0	For
Amplify ETF Trust	120	0	For

38. Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2023 Compensation Report: Binding vote on maximum equity for members of the Board of Directors from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders

COMPENSATION

Meeting held 2024-05-30.

98% fund support · no official result

FOR 98%

The 15 asset managers below cast 98% of the shares they voted on this item FOR (7,482,514 for, 148,898 against).

FOR: 7,482,514 (98.0%)AGAINST: 148,898 (2.0%)

Largest asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
ARK ETF Trust	7,426,282	0	For
Natixis	0	89,596	Against
Jackson National	34,217	34,215	For
ADVISORS SERIES TRUST	17,310	0	For
Loomis Sayles	0	9,378	Against
Allianz	0	6,152	Against
John Hancock	91	3,838	Against
AMG Funds I	0	3,641	Against
EA Series Trust	1,994	0	For
JPMorgan	1,297	0	For
Jacob Funds Inc.	1,203	0	For
TRUST FOR PROFESSIONAL MANAGERS	0	914	Against
CITY NATIONAL ROCHDALE FUNDS	0	664	Against
Pacer Funds Trust	0	500	Against
Amplify ETF Trust	120	0	For

39. Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2023 Compensation Report: Binding vote on maximum equity for members of the Executive Committee from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders

COMPENSATION

Meeting held 2024-05-30.

99.4% fund support · no official result

FOR 99.4%

The 15 asset managers below cast 99.4% of the shares they voted on this item FOR (7,590,755 for, 40,657 against).

FOR: 7,590,755 (99.5%)AGAINST: 40,657 (0.5%)

Largest asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
ARK ETF Trust	7,426,282	0	For
Natixis	89,596	0	For
Jackson National	43,484	24,948	For
ADVISORS SERIES TRUST	17,310	0	For
Loomis Sayles	9,378	0	For
Allianz	0	6,152	Against
John Hancock	91	3,838	Against
AMG Funds I	0	3,641	Against
EA Series Trust	1,994	0	For
JPMorgan	1,297	0	For
Jacob Funds Inc.	1,203	0	For
TRUST FOR PROFESSIONAL MANAGERS	0	914	Against
CITY NATIONAL ROCHDALE FUNDS	0	664	Against
Pacer Funds Trust	0	500	Against
Amplify ETF Trust	120	0	For

40. Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2023 Compensation Report: Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2024 to June 30, 2025

COMPENSATION

Meeting held 2024-05-30.

99.5% fund support · no official result

FOR 99.5%

The 15 asset managers below cast 99.5% of the shares they voted on this item FOR (7,595,560 for, 35,852 against).

FOR: 7,595,560 (99.5%)AGAINST: 35,852 (0.5%)

Largest asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2023-2024
Asset manager	For	Against	Vote
ARK ETF Trust	7,426,282	0	For
Natixis	89,596	0	For
Jackson National	43,484	24,948	For
ADVISORS SERIES TRUST	17,310	0	For
Loomis Sayles	9,378	0	For
Allianz	0	6,152	Against
John Hancock	91	3,838	Against
AMG Funds I	3,641	0	For
EA Series Trust	1,994	0	For
JPMorgan	1,297	0	For
Jacob Funds Inc.	1,203	0	For
TRUST FOR PROFESSIONAL MANAGERS	0	914	Against
CITY NATIONAL ROCHDALE FUNDS	664	0	For
Pacer Funds Trust	500	0	For
Amplify ETF Trust	120	0	For

Showing the 40 reported items with the widest manager coverage, of 60 in total. View every item.

Largest CRISPR THERAPEUTICS AG shareholders voting in 2023-2024

Ranked by the number of CRISPR THERAPEUTICS AG shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 84,837,610 shares outstanding at the time of that meeting.

Top CRISPR THERAPEUTICS AG shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	Capital Group	15.85%
2	ARK ETF Trust	8.75%
3	T. Rowe Price	4.41%
4	Nikko Asset Management Americas, Inc.	3.50%
5	Charles Schwab	1.58%
6	SR ONE CAPITAL MANAGEMENT, LP	1.24%
7	Vanguard	1.04%
8	UBS	0.78%
9	Contrarius Investment Management Ltd	0.77%
10	BlackRock	0.59%

Reported CRISPR THERAPEUTICS AG ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

CRISPR THERAPEUTICS AG beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
ARK Investment Management LLC	10.75%	13G
BlackRock	8.31%	13F
Capital Research and Management Company	7.57%	DEF14A
Vanguard Group	2.79%	13F
FMR (Fidelity)	2.22%	13F
Citadel Advisors	1.84%	13F
State Street	1.76%	13F
Samarth Kulkarni, Ph.D.	1.69%	DEF14A
Morgan Stanley	1.65%	13F
Simeon J. George, M.D.	1.38%	DEF14A

Percentages above are of 84,837,610 shares outstanding, as reported by CRISPR THERAPEUTICS AG on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CRISPR THERAPEUTICS AG’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At CRISPR THERAPEUTICS AG's shareholder meeting held 2024-05-30, in the 2023-2024 proxy season, 445 asset managers reported how they voted in their SEC Form N-PX filings, covering 5,335 separate fund positions. Their filings are grouped here into 60 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. CRISPR THERAPEUTICS AG's own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Non-binding advisory vote on the compensation paid to the Company's named executive officers… — the reporting funds cast 77% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

CRISPR THERAPEUTICS AG proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.